BBK Worldwide has coupled its reputation with the singular idea that placing patient and caregiver needs as the first priority for clinical research is a win-win for all involved. For more than twenty years, BBK has promoted the company tagline, “The Patients to Find the Cure.” Having moved our collected perspectives from the days where BBK was criticized for referring to “subjects” as “patients,” the current research environment reveres “patient centricity” as the industry mantra. So, what’s next? A new concern shrouds our efforts. The notion that technological solutions are at the root of patient-centric care, in fact, may defeat the very goal the industry wishes to accomplish.
Medication non-compliance is an epidemic that impacts patients, sponsors and the healthcare industry at large, costing the U.S. healthcare system around 300 billion dollars a year. According to a PM360 article that highlights medication compliance in diabetes patient populations, non-adherent patients have inpatient healthcare costs that are 41% higher than those of adherent patients.
The clinical research industry is unique among other industries for many reasons. Yet in the bigger picture, the way we interact with information has evolved, more or less, in step with the rest of the world. I can see parallels between changes in my own life and how clinical trials, and patient recruitment and engagement, have changed over the years.
It’s the greatest time of the year, well at least in my opinion. It’s March Madness. For those of you who don’t know, every year in March the NCAA basketball tournament captures the eye of the sporting world, consisting of brackets, upsets, buzzer beaters, and heartbreak.
Where am I going with this? As I sit in my office, I think about some of the biggest issues that face the clinical trial industry regarding the adoption and implementation of new products.
Nearly a year ago, we released our first guide on rare disease clinical research. In it, we were looking to address some important questions facing the people who are committed to improving the lives of patients with rare disorders. While much progress has been made, it is critical that those of us in the health care and life sciences industry remain keenly aware of all that’s being done to further research and improve outcomes. In our latest eBook, “Focus 5: Rare Disease Research. What’s Next?” we reached out to industry experts for their insights on this evolving clinical research landscape.
Patient centricity has become an essential element of modern healthcare – in part thanks to the tenacity of patients and caregivers. They have advocated for a place at the table with sponsors and researchers in the drug development process, informing clinical and therapeutic research with much-needed patient voice and perspective.
During last week’s webinar with BBK President Matt Kibby and Roche’s Operational Intelligence Leader, Lewis Millen, on “Harnessing the Power of mHealth for New, Better Data and Improved Patient Engagement,” we had the opportunity to cover a variety of topics and challenges related to mHealth adoption and deployment. And we were pleased to have so many representatives from all areas of clinical R&D, including patients, join us. Lewis was able to provide such valuable insights and if you joined us, you know that first hand.
About this time each year I blog about how much I hate cancer. This year, it’s a bit tougher as my father was diagnosed with advanced head and neck cancer in June. Once again I am reminded about the difference it makes to be knowledgeable about clinical trials when making treatment decisions. We ask more questions. We explore more options. We filter what we hear through experience. And, we know when the informed consent process isn’t being done well – or even in compliance with regulations.
If you follow Humans of New York (HONY) on Facebook – and with more than 17 million followers, I expect you do – then you’ve been inspired by and often heartsick over this week’s stories told from the Pediatrics Department of Memorial Sloan Kettering Cancer Center.
It feels like we’re always on our mobile devices. But what exactly are we doing when we’re on them? Sure, we make phone calls, check email, and browse the web. But in terms of average mobile usage, we spend nearly 80 percent of our time in apps. With many of those apps being supported through paid advertisements, in-app advertising is creating exciting new opportunities for clinical trial marketers to identify, segment, and target potential participants inside the mobile universe.